If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance. The U.S. Food and Drug Administration (FDA) has notified prescribers that topiramate can cause acute myopia and secondary angle closure glaucoma in a small subset of people who take a lot of topiramate. The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage and may reverse the visual impairment. Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations. This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in Pregnancy Category D. Cognitive and word-finding difficulties, which may occur in some patients, may respond to piracetam. Carbonation dysgeusia (distortion of the sense of taste-sensation of carbonation) may respond to and/or be prevented with zinc. Topiramate has been associated with a statistically significant increase in suicidality, and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."
Cuban Assets Control Regulations of 1963 Cuban Democracy Act of 1992 Helms–Burton Act of 1996 (Cuba) Iran and Libya Sanctions Act of 1996 Trade Sanction Reform and Export Enhancement Act of 2000 (Cuba) Iran Freedom and Support Act of 2006 Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010
Ortho Clinical Diagnostics (now QuidelOrtho) is an in vitro diagnostics company that made products and diagnostic equipment for blood testing. Ortho served two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood. Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. QuidelOrtho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York. In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operated as an independent company, up until its acquisition by Quidel Corporation for $6 billion, on May 27, 2022.
==== Thiopeptides ==== Thiopeptide biosynthesis involves particularly extensive modification of the core peptide scaffold. Indeed, due to the highly complex structures of thiopeptides, it was commonly thought that these natural products were nonribosomal peptides. Recognition of the ribosomal origin of these molecules came in 2009 with the independent discovery of the gene clusters for several thiopeptides. The standard nomenclature for thiopeptide biosynthetic proteins follows that of the thiomuracin gene cluster. In addition to the precursor peptide, referred to as the A peptide, thiopeptide biosynthesis requires at least six genes. These include lanthipeptide-like dehydratases, designated the B and C proteins, which install dehydroalanine and dehydrobutyrine moieties by dehydrating Ser/Thr precursor residues. Azole and azoline synthesis is effected by the E protein, the dehydrogenase, and the G protein, the cyclodehydratase. The nitrogen-containing heterocycle is installed by the D protein cyclase via a putative [4+2] cycloaddition of dehydroalanine moieties to form the characteristic macrocycle. The F protein is responsible for binding of the leader peptide. Thiopeptide biosynthesis is biochemically similar to that of cyanobactins, lanthipeptides, and linear azol(in)e-containing peptides (LAPs). As with cyanobactins and LAPs, azole and azoline synthesis occurs via the action of an ATP-dependent YcaO-domain cyclodehydratase.
=== Oil-water separation === Nanofibers have the capabilities in oil–water separation, most particularly in sorption process when the material in use has the oleophilic and hydrophobic surfaces. These characteristic enable the nanofibers to be used as a tool to combat either oily waste- water from domestic household and industrial activities, or oily seawater due to the oil run down to the ocean from oil transportation activities and oil tank cleaning on a vessel.
Sources: en.wikipedia.org
== Function == GPVI is a 58-kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. Upon injury to the vessel wall and subsequent damage to the endothelial lining, exposure of the subendothelial matrix to blood flow results in deposition of platelets. Collagen fibers are the most thrombogenic macromolecular components of the extracellular matrix, with collagen types I, III, and VI being the major forms found in blood vessels. Platelet interaction with collagen occurs as a 2-step procedure: (1) the initial adhesion to collagen is followed by (2) an activation step leading to platelet secretion, recruitment of additional platelets, and aggregation. In physiologic conditions, the resulting platelet plug is the initial hemostatic event limiting blood loss. However, exposure of collagen after rupture of atherosclerotic plaques is a major stimulus of thrombus formation associated with myocardial infarction or stroke. Complete or partial deficiency of GPVI in humans is a rare condition presenting as a mild bleeding disorder.
They also stressed that the TWG had given too much credence to the chemistry experiments performed by the Russians, considered the TWG's retrospective treatment of the Russian work based on unpublished documents to have been "highly irregular", noted that there was no proof that 259Rf had a spontaneous fission branch at all (as of 2021 there still is not), and accused the TWG of not having appropriately qualified personnel on the committee. The TWG responded by saying that this was not the case and having assessed each point raised by the American group said that they found no reason to alter their conclusion regarding priority of discovery. The International Union of Pure and Applied Chemistry (IUPAC) adopted unnilquadium (Unq) as a temporary, systematic element name, derived from the Latin names for digits 1, 0, and 4. In 1994, IUPAC suggested a set of names for elements 104 through 109, in which dubnium (Db) became element 104 and rutherfordium became element 106. This recommendation was criticized by the American scientists for several reasons. Firstly, their suggestions were scrambled: the names rutherfordium and hahnium, originally suggested by Berkeley for elements 104 and 105, were respectively reassigned to elements 106 and 108. Secondly, elements 104 and 105 were given names favored by JINR, despite earlier recognition of LBL as an equal co-discoverer for both of them.
On the same day, the talks between the US and Iran—the highest-level discussions between the two since the 1979 Islamic Revolution—were held in Islamabad, Pakistan, lasting 21 hours. JD Vance announced no agreement was reached and Iran had refused "to accept our terms". Trump stated he no longer cared about negotiations. Trump declared that the US Navy would begin its blockade of "all Ships trying to enter, or leave, the Strait of Hormuz" from 13 April. He said the US Navy would stop any ships that paid tolls to Iran. However, United States Central Command clarified that the blockade would only be enforced on ships traveling to or from Iranian ports. The IRGC Navy said any military vessel approaching the strait would be considered a ceasefire violation and meet a "severe response." Trump threatened to strike fast-attack ships of the IRGC Navy, similar to US strikes on drug traffickers during Operation Southern Spear. Iran had 13 days of oil storage capacity, forcing it to shut down its oil fields and potentially damaging them. An analyst estimated loss of import and export capacity would be US$435 million per day. On 16 April, Trump announced that Israel and Lebanon agreed to a ten-day truce. Iran announced that passage of commercial vessels through the strait would be allowed during the truce, however, Trump said that the blockade would continue, with Iran reimposing restrictions on the strait. The US stated that its blockade had intercepted 23 ships. Despite Iran's seizure of two cargo ships, Trump claimed total control over the strait.
== Methods == Chumming is a common practice seen as effective by fishermen all over the world, typically in open oceans. Multiple forms of chum are available and used by anglers. Bunker consists of fish parts with a fish-enticing aroma. Stink bait contains oily fish parts and blood that releases the scent of dead fish into the water. Sour grain is a commonly used form of chum bait when fishing for catfish in inland waters of the Southern United States. Native Americans used two methods of chumming. First, they would lie alongside a grasshopper and encourage it to jump into a flowing stream where the fish would consume the grasshopper. The Native Americans would then bait their hook with a grasshopper and hence catch the fish. Additionally, indigenous people would tie a dead animal from a tree above a stream encouraging flies to lay eggs. After weeks, the eggs became maggots and fell into the water, bringing a concentration of fish into the area.
Sources: en.wikipedia.org
=== Norway === The appointment of Isabel Soria Reátegui as ambassador to Norway in July 2022 sparked a scandal because Soria had no university education or diplomatic background, instead being a member of Perú Libre and a campaign coordinator in Sweden. To enable her appointment, the Peruvian foreign ministry summarized and edited Soria's curriculum vitae to remove unnecessary information and correct spelling mistakes. However, this situation led Soria to accuse the foreign ministry of discrediting her by editing her curriculum, complaining to Castillo and requesting that he send Norway a new version of her curriculum. In response, the foreign ministry sent a new curriculum to Norway, including the unnecessary information and spelling mistakes.
It is possible to distinguish these sources by analyzing this oil by high-temperature gas chromatography–mass spectrometry. The oil and plasticizer must be separated from the C-4 sample, typically by using a non-polar organic solvent such as pentane followed by solid phase extraction of the plasticizer on silica. This method of analysis is limited by manufacturing variation and methods of distribution.
On August 22, 2018, Alice in Chains sent fans on a scavenger hunt to access a secret gig that the band would be performing in Seattle on August 24. Ten signed CD copies of Rainier Fog were hidden around the city as a ticket into the show, and the band asked the fans to keep an eye on their Instagram story for details on the 10 hidden locations. Once all 10 albums were found, the band revealed that the secret gig would be at the rock club The Crocodile, with limited tickets available with the purchase of their album at a pop-up event at the same venue the next day. Preview clips of each of the album tracks were posted on the band's Instagram. The band also commemorated the release of the album with a pop-up museum installation at The Crocodile in Seattle on August 23 and 24. The museum featured rare Alice in Chains photos, limited-edition merchandise and memorabilia that showcased the band's 30+ year career. Rainier Fog debuted at No. 12 on the Billboard 200 chart, selling 31,000 copies (29,000 in traditional album sales), in its first week of release. The album also debuted at No. 1 on Billboard's Top Rock Albums, Alternative Albums and Hard Rock Albums charts, and at No. 3 on the Vinyl Albums chart. Rainier Fog became Alice in Chains' first top 10 in the UK, peaking at No. 9, and topping UK's Rock & Metal Albums chart. The album has been nominated for a Grammy Award for Best Rock Album.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.